{
  "ticker": "RARE",
  "company_name": "Ultragenyx Pharmaceutical Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05139316",
      "title": "A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Glycogen Storage Disease Type IA",
      "start_date": "2021-11-08",
      "completion_date": "2026-02",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT02097251",
      "title": "An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient",
      "status": "NO_LONGER_AVAILABLE",
      "phase": "",
      "condition": "Mucopolysaccharidosis Type 7",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Joyce Fox"
    },
    {
      "nct_id": "NCT05783791",
      "title": "Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Angelman Syndrome, Prader-Willi Syndrome",
      "start_date": "2023-04-20",
      "completion_date": "2023-07-21",
      "enrollment": 0,
      "sponsor": "University of Wisconsin, Madison"
    },
    {
      "nct_id": "NCT03216486",
      "title": "An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta",
      "status": "WITHDRAWN",
      "phase": "PHASE2",
      "condition": "Osteogenesis Imperfecta",
      "start_date": "2017-10-31",
      "completion_date": "2018-11-01",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT01784679",
      "title": "GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Hereditary Inclusion Body Myopathy, GNE Myopathy, Nonaka Disease, Quadriceps Sparing Myopathy (QSM), Distal Myopathy With Rimmed Vacuoles (DMRV)",
      "start_date": "2013-04-05",
      "completion_date": "2017-11-30",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT03642860",
      "title": "The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Tarui Disease, Debrancher Deficiency, GYG1 DEFICIENCY",
      "start_date": "2018-08-15",
      "completion_date": "2019-08-28",
      "enrollment": 0,
      "sponsor": "Rigshospitalet, Denmark"
    },
    {
      "nct_id": "NCT02960217",
      "title": "Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)",
      "start_date": "2017-04-19",
      "completion_date": "2019-10-09",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT02036853",
      "title": "An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)",
      "start_date": "2014-02-20",
      "completion_date": "2019-06-30",
      "enrollment": 0,
      "sponsor": "Adrian Lacy"
    },
    {
      "nct_id": "NCT02731690",
      "title": "A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Hereditary Inclusion Body Myopathy, Distal Myopathy With Rimmed Vacuoles, Distal Myopathy, Nonaka Type, GNE Myopathy, Quadriceps Sparing Myopathy, Inclusion Body Myopathy 2",
      "start_date": "2016-04-29",
      "completion_date": "2018-01-10",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT02377921",
      "title": "Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Hereditary Inclusion Body Myopathy, Distal Myopathy With Rimmed Vacuoles, Distal Myopathy, Nonaka Type, GNE Myopathy",
      "start_date": "2015-05-20",
      "completion_date": "2017-06-09",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE3": 9,
      "": 16,
      "PHASE2": 15,
      "EARLY_PHASE1": 2,
      "PHASE2, PHASE3": 2,
      "PHASE1, PHASE2": 6
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 8,
      "NO_LONGER_AVAILABLE": 2,
      "COMPLETED": 23,
      "WITHDRAWN": 2,
      "TERMINATED": 6,
      "ENROLLING_BY_INVITATION": 3,
      "UNKNOWN": 1,
      "RECRUITING": 4,
      "SUSPENDED": 1
    },
    "active_trials": 15,
    "completed_trials": 23,
    "conditions": [
      "ALS",
      "Acid Sphingomyelinase Deficiency, Ceroid Lipofuscinosis, Neuronal, 2, Cerebrotendinous Xanthomatosis, Fabry Disease, GM1 Gangliosidosis, Gaucher Disease, Lysosomal Acid Lipase Deficiency, Metachromatic Leukodystrophy, Mucopolysaccharidosis II, Mucopolysaccharidosis III-B, Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidosis VII, Niemann-Pick Disease, Type C",
      "Angelman Syndrome",
      "Angelman Syndrome, Prader-Willi Syndrome",
      "Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency, Trifunctional Protein (TFP) Deficiency, Carnitine-acylcarnitine Translocase (CACT) Deficiency",
      "Chronic-kidney Disease Stage 5D on Stable Hemodialysis",
      "Creatine Deficiency, X-linked",
      "Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome",
      "GNE Myopathy, Hereditary Inclusion Body Myopathy",
      "GSD1",
      "Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)",
      "Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)",
      "Glycogen Storage Disease Type I",
      "Glycogen Storage Disease Type IA",
      "Glycogen Storage Disease Type IA, Von Gierke's Disease (GSD Type Ia)",
      "Glycogen Storage Disease Type III",
      "Glycogen Storage Disease Type Ia",
      "Glycogen Storage Disease Type V",
      "Hemophilia B",
      "Hereditary Inclusion Body Myopathy, Distal Myopathy With Rimmed Vacuoles, Distal Myopathy, Nonaka Type, GNE Myopathy",
      "Hereditary Inclusion Body Myopathy, Distal Myopathy With Rimmed Vacuoles, Distal Myopathy, Nonaka Type, GNE Myopathy, Quadriceps Sparing Myopathy, Inclusion Body Myopathy 2",
      "Hereditary Inclusion Body Myopathy, GNE Myopathy, Nonaka Disease, Quadriceps Sparing Myopathy (QSM), Distal Myopathy With Rimmed Vacuoles (DMRV)",
      "Homozygous Familial Hypercholesterolemia",
      "Huntington Disease",
      "Hypophosphatemia, Hypophosphatemic Rickets, Pain, Chronic",
      "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)",
      "MPS IIIA, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis III",
      "Medium-chain Acyl-CoA Dehydrogenase Deficiency",
      "Mucopolysaccharidoses, Carotid Disease, Cardiac Disease, Inflammation",
      "Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A",
      "Mucopolysaccharidosis Type 7",
      "Mucopolysaccharidosis VII, MPS VII, MPS 7, Sly Syndrome",
      "Ornithine Transcarbamylase (OTC) Deficiency",
      "Osteogenesis Imperfecta",
      "Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV",
      "Osteopenia, Osteoporosis",
      "Sly Syndrome, MPS VII, Mucopolysaccharidosis, Mucopolysaccharidosis VII",
      "Tarui Disease, Debrancher Deficiency, GYG1 DEFICIENCY",
      "Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2), Mitochondrial Trifunctional Protein Deficiency, Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency, Glycogen Storage Disorders, Pyruvate Carboxylase Deficiency Disease, ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9, DEFICIENCY of, Barth Syndrome",
      "Wilson Disease",
      "X-linked Hypophosphatemia, Hypophosphatemic Rickets"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:21:21.432116",
    "search_query": "Ultragenyx Pharmaceutical Inc.",
    "url": "https://clinicaltrials.gov/search?term=Ultragenyx+Pharmaceutical+Inc."
  }
}